Curis and Debiopharm Group(TM) Announce Initiation of Phase I Dose Finding ... GlobeNewswire (press release) This dose escalation study is designed to determine the safety and maximum tolerated dose of Debio 0932 in combination with everolimus, in previously treated patients with advanced/metastatic RCC. The pharmacokinetic profiles and any potential drug ... |
